PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8718563-2 1996 An initial single dose of 1 mg of cilazapril given at the end of the HD session produced a marked improvement in the interdialysis thirst scores and a simultaneous reduction in plasma angiotensin II (AII) concentration due to the inhibition of ACE activity. Cilazapril 34-44 angiotensinogen Homo sapiens 184-198 22622687-4 2013 After recovery from acute exacerbation of congestive heart failure by tolvaptan administration, an ACEI (cilazapril) was started to decrease the production of angiotensin II, which upregulates serum antidiuretic hormone secretion. Cilazapril 105-115 angiotensinogen Homo sapiens 159-173 9524014-2 1998 We established the effect of long-term treatment with cilazapril, an angiotensin-converting enzyme inhibitor, which prevents the effect of angiotensin II in the tonic control of vascular resistance. Cilazapril 54-64 angiotensinogen Homo sapiens 139-153 9012741-11 1997 Finally, angiotensin II was measured in the perfusate of the carotid artery and was found to be released at a rate of 11.9 +/- 2.2 pg in 60 minutes (n = 8), which was significantly decreased to 1.4 +/- 0.4 pg in 60 minutes (n = 4) by cilazapril (1 mumol/L). Cilazapril 234-244 angiotensinogen Homo sapiens 9-23 8718563-2 1996 An initial single dose of 1 mg of cilazapril given at the end of the HD session produced a marked improvement in the interdialysis thirst scores and a simultaneous reduction in plasma angiotensin II (AII) concentration due to the inhibition of ACE activity. Cilazapril 34-44 angiotensinogen Homo sapiens 200-203 8718563-5 1996 The present data help to explain the potential pharmacological action of AII in the physiology of thirst and suggest that cilazapril may effectively alleviate dialysis-associated hyperdipsia at least on some occasions. Cilazapril 122-132 angiotensinogen Homo sapiens 73-76 8219659-10 1993 Following furosemide angiotensin II increased significantly even after cilazapril pretreatment. Cilazapril 71-81 angiotensinogen Homo sapiens 21-35 7898090-5 1994 We showed that single oral doses of cilazapril 4 mg, captopril 25 mg, or enalapril 10 mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacologic half-life of about 4 h for cilazapril. Cilazapril 36-46 angiotensinogen Homo sapiens 101-114 7898090-6 1994 Increasing single oral doses (1.25, 3.75, 10, and 30 mg) of cilazapril reduced diastolic blood pressure dose-dependently and shifted the angiotensin I dose-response curves to the right. Cilazapril 60-70 angiotensinogen Homo sapiens 137-150 8219659-13 1993 The study shows that (a) cilazapril increases furosemide-induced natriuresis irrespective of salt intake, (b) antinatriuresis is not affected by cilazapril, and (c) angiotensin II levels rise after furosemide on cilazapril in therapeutic doses. Cilazapril 25-35 angiotensinogen Homo sapiens 165-179 1382161-0 1992 Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. Cilazapril 71-81 angiotensinogen Homo sapiens 17-31 7682991-10 1993 These findings indirectly suggest that most, if not all, of the renal effects of cilazapril are mediated through suppression of Ang II formation. Cilazapril 81-91 angiotensinogen Homo sapiens 128-134 1382161-3 1992 This suggests that hourly changes in Ang II concentrations and/or in Ang II receptor density after short-term administration of the angiotensin-converting enzyme (ACE) inhibitor cilazapril does not significantly affect renal vascular reactivity. Cilazapril 178-188 angiotensinogen Homo sapiens 37-43 1382161-3 1992 This suggests that hourly changes in Ang II concentrations and/or in Ang II receptor density after short-term administration of the angiotensin-converting enzyme (ACE) inhibitor cilazapril does not significantly affect renal vascular reactivity. Cilazapril 178-188 angiotensinogen Homo sapiens 69-75 1712266-2 1991 The specificity of the angiotensin I infusion method was verified when a single dose of cilazapril 30mg antagonised the increase in diastolic blood pressure induced by angiotensin I but did not influence the response to angiotensin II. Cilazapril 88-98 angiotensinogen Homo sapiens 23-36 1712266-2 1991 The specificity of the angiotensin I infusion method was verified when a single dose of cilazapril 30mg antagonised the increase in diastolic blood pressure induced by angiotensin I but did not influence the response to angiotensin II. Cilazapril 88-98 angiotensinogen Homo sapiens 168-181 1712266-3 1991 Using this method, we showed that single oral doses of cilazapril 4 mg, captopril 25 mg and enalapril 10mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacological half-life of about 4 hours for cilazapril. Cilazapril 55-65 angiotensinogen Homo sapiens 119-132 1712266-3 1991 Using this method, we showed that single oral doses of cilazapril 4 mg, captopril 25 mg and enalapril 10mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacological half-life of about 4 hours for cilazapril. Cilazapril 228-238 angiotensinogen Homo sapiens 119-132 1712266-4 1991 Increasing single oral doses (1.25, 3.75, 10 and 30mg) of cilazapril reduced diastolic blood pressure dose-dependently and shifted the angiotensin I dose-response curves to the right. Cilazapril 58-68 angiotensinogen Homo sapiens 135-148 2531608-5 1989 The angiotensin I effects were completely abolished after the administration of cilazapril but not significantly altered after the administration of prazosin. Cilazapril 80-90 angiotensinogen Homo sapiens 4-17 2146394-2 1990 Angiotensin II infusion caused dose-related increases in blood pressure and reductions in cortical perfusion, the latter responses being potentiated in the presence of the converting enzyme inhibitor, cilazapril. Cilazapril 201-211 angiotensinogen Homo sapiens 0-14 2527544-6 1989 Cilazapril induced a pronounced increase of plasma renin activity and angiotensin I concentrations, whereas after propranolol both parameters decreased. Cilazapril 0-10 angiotensinogen Homo sapiens 70-83 2476598-0 1989 Cilazapril and enalapril inhibit local angiotensin I conversion in human veins but lack direct venodilating properties. Cilazapril 0-10 angiotensinogen Homo sapiens 39-52 2548551-8 1989 Cilazapril shifted the angiotensin I dose-response curves to the right. Cilazapril 0-10 angiotensinogen Homo sapiens 23-36 2548552-4 1989 We therefore investigated whether cilazapril, a structurally new and long-acting ACE inhibitor, interacts with angiotensin I-dependent changes in splanchnic haemodynamics in man, using an experimental model. Cilazapril 34-44 angiotensinogen Homo sapiens 111-124 2548552-11 1989 The angiotensin I dependent increase in systemic and pulmonary resistance and pulmonary capillary wedge pressure was attenuated by cilazapril, as indicated by the shift of the dose-response curves to the right. Cilazapril 131-141 angiotensinogen Homo sapiens 4-17 2548552-13 1989 These angiotensin I induced haemodynamic changes were clearly suppressed by cilazapril. Cilazapril 76-86 angiotensinogen Homo sapiens 6-19 2548552-17 1989 We conclude that, in man, the influence of cilazapril on acute angiotensin I-mediated haemodynamic responses is present in the splanchnic vascular bed, and that the overall effects of cilazapril are consistent with both arterial and venous effects of the ACE inhibitor. Cilazapril 43-53 angiotensinogen Homo sapiens 63-76 2548552-18 1989 Cilazapril effectively counteracts angiotensin I-induced splanchnic vasoconstriction. Cilazapril 0-10 angiotensinogen Homo sapiens 35-48 2974715-11 1988 Propranolol shifted the isoprenaline dose-effect curve to the right, and cilazapril that of angiotensin I, irrespective of the presence of the other drug. Cilazapril 73-83 angiotensinogen Homo sapiens 92-105 2436002-2 1987 We used this principle to characterize the interaction between angiotensin I (AI) and the angiotensin-converting enzyme (ACE) inhibitor cilazapril in humans. Cilazapril 136-146 angiotensinogen Homo sapiens 63-76 2436002-2 1987 We used this principle to characterize the interaction between angiotensin I (AI) and the angiotensin-converting enzyme (ACE) inhibitor cilazapril in humans. Cilazapril 136-146 angiotensinogen Homo sapiens 78-80 2436002-3 1987 In addition, by comparing the effects of AI and angiotensin II before and after administration of a 30-mg dose of cilazapril, we could show the specific AI antagonism of the ACE inhibitor in humans. Cilazapril 114-124 angiotensinogen Homo sapiens 41-43 2436002-3 1987 In addition, by comparing the effects of AI and angiotensin II before and after administration of a 30-mg dose of cilazapril, we could show the specific AI antagonism of the ACE inhibitor in humans. Cilazapril 114-124 angiotensinogen Homo sapiens 48-62 2436002-3 1987 In addition, by comparing the effects of AI and angiotensin II before and after administration of a 30-mg dose of cilazapril, we could show the specific AI antagonism of the ACE inhibitor in humans. Cilazapril 114-124 angiotensinogen Homo sapiens 153-155 2436002-7 1987 Cilazapril dose dependently shifted the AI dose-response curve rightward, with 1.0 mg inducing a twofold shift. Cilazapril 0-10 angiotensinogen Homo sapiens 40-42 3034469-0 1987 Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers. Cilazapril 40-50 angiotensinogen Homo sapiens 14-27 3034469-4 1987 Additionally the response to AT-I was established before, during, and after cessation of a 15-day 2.5 mg/day cilazapril administration. Cilazapril 109-119 angiotensinogen Homo sapiens 29-33